Integra LifeSciences Holdings (IART)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Integra LifeSciences Holdings.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 17.90 $ — 82% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 5.7%
- Exp. sales growth 3Y > 5% 2.8%
- EBIT growth 10Y > 5% -5.7%
- Exp. EBIT growth 3Y > 5% 2.8%
- Net debt < 4x EBIT 25.9x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 88.1%
- Return on equity > 15% –
- ROCE > 15% 2.2%
- Expected return > 10% -0.6%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 1.6% failed
- More than 10% revenue growth is expected for the coming year 3.3% failed
- Share count grows by less than 3% a year -2.8% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -1.2% failed
- Gross margin at 40% or higher and without meaningful erosion 51.7% failed
- Goodwill from acquisitions does not grow faster than revenue 17.1% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 775 m passed
- Return on capital at 15% or higher, or up versus two years ago 2.2% failed
- Insiders hold at least 10% or are net buyers 14.3% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 9.3% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.46 | 2.41 – 2.50 | 1,674 | 10.2% | 12 |
| 12/31/2027 | 2.61 | 2.50 – 2.73 | 1,728 | 6.0% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.25 | -0.30 | 443 | 11.50 | 4.40 | 51 | 11 |
| 2025: Q1 | -0.33 | – | 383 | 3.70 | -6.60 | -11 | -40 |
| 2025: Q2 | -6.33 | – | 416 | -0.60 | -116.50 | 9 | -11 |
| 2025: Q3 | -0.07 | – | 402 | 5.60 | -1.30 | 41 | 26 |
| 2025: Q4 | -0.02 | -108.80 | 435 | -1.70 | -0.40 | 12 | -20 |
| 2026: Q1 | -0.06 | – | 392 | 2.40 | -1.20 | 10 | -5 |
| 2026: Q2 | 0.06 | 100.90 | 419 | 0.80 | 1.10 | 23 | 11 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 992 | 115 | 75 | 0.94 | 116 | 840 | 1,808 |
| 2017 | 1,188 | 45 | 65 | 0.82 | 115 | 962 | 3,211 |
| 2018 | 1,472 | 111 | 61 | 0.72 | 200 | 1,376 | 3,108 |
| 2019 | 1,518 | 94 | 50 | 0.58 | 231 | 1,417 | 3,303 |
| 2020 | 1,372 | 151 | 134 | 1.57 | 204 | 1,515 | 3,615 |
| 2021 | 1,542 | 197 | 169 | 1.98 | 312 | 1,685 | 3,782 |
| 2022 | 1,558 | 239 | 181 | 2.16 | 264 | 1,804 | 3,890 |
| 2023 | 1,542 | 112 | 68 | 0.84 | 140 | 1,588 | 3,782 |
| 2024 | 1,611 | 28 | -7 | -0.09 | 129 | 1,545 | 4,037 |
| 2025 | 1,635 | 68 | -516 | -6.73 | 50 | 1,043 | 3,602 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Integra LifeSciences Holdings Corporation stellt chirurgische Instrumente sowie neurochirurgische, HNO- und Wundversorgungsprodukte für den Einsatz in der Neurochirurgie, der neurologischen Intensivmedizin und der HNO-Heilkunde her und verkauft sie. Es ist in den Segmenten Codman Specialty Surgical und Tissue Technologies tätig.
| Employees | 4,427 |
|---|---|
| Headquarters | Princeton, NJ |
| Address | 1100 Campus Road, 08540 Princeton, United States |
| Phone | 609 275 0500 |
| Website | integralife.com |
| IPO Date | 16. Aug 1995 |
| ISIN | US4579852082 |
| Stock Split | 2:1 on 01/04/2017 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Stuart M. Essig Ph.D. | CEO, President & Chairman | 1962 |
| Lea Daniels Knight | Executive VP & CFO | 1972 |
| Robert T. Davis Jr. | Executive Vice President of Tissue Reconstruction and Distributed Technologies | 1959 |
| Michael J. McBreen | Executive VP & Chief Commercial Officer | 1966 |
| Harvinder Pal Singh | Executive VP & President of International Business | 1966 |
| Jeffrey A. Mosebrook | Senior VP of Finance & Principal Accounting Officer | 1976 |
| Teshtar Elavia | Corporate VP & Chief Technology Officer | – |
| Christopher Ward | Senior Director of Investor Relations | – |
| Michael D. Hutchinson | Executive VP, Chief Legal Officer & Secretary | 1971 |
| Laurene Isip | Vice President of Global Corporate Communications & Public Relations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.